Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of carbidopa monohydrate丨cas 38821-49-7 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
↵
Specifications
| Grade | USP43 grade |
| Appearance | White or creamy white powder, odorless or practically odorless |
| Assay | 98.0% to 102.0% |
| Solubility | Slightly soluble in water, freely soluble in 3N hydrochloride acid; slightly soluble in methanol; practically insoluble in alcohol, acetone, chloroform, and ether |
| Identification | A: IR: The external light absorption spectrum of the tested magenta should be consistent with the reference spectrum B: Assay: RT: The retention time of the main peak should be consistent with the reference substance |
| Ignition residue | 0.1% max |
| Carbidopa related compound A | 0.5% max |
| Total impurities | 1.0% max |
| Any other impurity | 0.1% max |
| Specific rotation | -21.0° ~ -23.5° |
| Loss on drying | 6.9 ~ 7.9% |
| Methyldopa | 0.5% max |
| Methanol | 3000 ppm max |
| 2-propanol | 5000 ppm max |
| Chloroform | 60 ppm max |
| Benzene | 2 ppm max |
| Toluene | 890 ppm max |
| Cyclohexanone | 20 ppm max |
Applications
Carbidopa Monohydrate is primarily used in combination therapy with levodopa for the management of Parkinson's disease and related movement disorders. In Parkinson's patients, levodopa is converted to dopamine in the brain, which helps alleviate motor symptoms such as tremors, rigidity, and bradykinesia. Carbidopa inhibits peripheral decarboxylation of levodopa, ensuring more of the administered levodopa reaches the central nervous system. Beyond Parkinson's, Carbidopa Monohydrate finds application in research settings for developing formulations that enhance bioavailability and reduce side effects of dopaminergic treatments. Its presence in combination drugs allows for optimized dosing regimens, improved patient adherence, and exploration of extended-release formulations for sustained symptom management.
Benefits
The key benefit of Carbidopa Monohydrate lies in its ability to increase the efficacy of levodopa therapy while minimizing peripheral side effects such as nausea, vomiting, and cardiovascular complications. By preventing the premature conversion of levodopa into dopamine outside the brain, Carbidopa reduces the required dose of levodopa, thereby improving safety and tolerability. This synergistic effect leads to more consistent symptom control, smoother motor function, and improved quality of life for patients. Additionally, Carbidopa contributes to longer therapeutic windows and more stable plasma concentrations of levodopa, which is particularly beneficial in reducing "off" periods and motor fluctuations commonly experienced in advanced stages of Parkinson's disease. Its integration into clinical protocols has made it a cornerstone in modern dopaminergic therapy, supporting both short-term symptom relief and long-term management strategies.
Conclusion
Carbidopa Monohydrate is an essential pharmaceutical agent in the treatment of Parkinson's disease, enhancing the efficacy and safety of levodopa therapy. Its role in reducing peripheral side effects and improving central availability of dopamine makes it a vital component in combination therapies, contributing significantly to patient comfort and functional independence. Beyond therapeutic applications, it serves as a key molecule in research for improved drug delivery and formulation design. Overall, Carbidopa Monohydrate exemplifies how targeted enzyme inhibition can optimize treatment outcomes, ensuring both effectiveness and tolerability in chronic neurological management.
